Skip to main content
Log in

Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters

  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Three methods approved by the National Committee for Clinical Laboratory Standards for testing the susceptibility of anaerobic bacteria were used to evaluate the fluoroquinolone, trovafloxacin. The methods gave essentially comparable results with 126 anaerobes and with three quality control strains. A collaborative study defined the quality control range for trovafloxacin MICs. Trovafloxacin had good in vitro activity against the more common anaerobes (MIC 90 <- 2.0 (Μg/ml).

Trovafloxacin (CP-99,219) is a fluoroquinolone with a broad spectrum of antibacterial activity (1–3). Its in vitro spectrum includes many anaerobic bacteria (4).The National Committee for Clinical Laboratory Standards (NCCLS) currently recommends three different methods for testing the susceptibility of anaerobic bacteria (5). The standard reference method is an agar dilution procedure using Wilkins-Chalgren agar. Two alternative methods are an agar dilution technique using Brucella blood agar and a microdilution procedure using a broth version of Wilkins-Chalgren medium. It is important to determine whether these three procedures actually produce identical test results with each antimicrobial agent likely to be tested against anaerobes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366–370.

    PubMed  Google Scholar 

  2. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349–353 (Erratum, 38:909).

    PubMed  Google Scholar 

  3. Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2615–2622.

    PubMed  Google Scholar 

  4. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471–2476.

    Google Scholar 

  5. National Committee for Clinical Laboratory Standards: Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A3. NCCLS, Villanova, PA, 1993.

    Google Scholar 

  6. Barry AL, Fuchs PC, Citron DM, Allen SD, Wexler HM: Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. Journal of Antimicrobial Chemotherapy 1993, 31: 893–900.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barry, A.L., Fuchs, P.C., Thornsberry, C. et al. Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters. Eur. J. Clin. Microbiol. Infect. Dis. 15, 676–678 (1996). https://doi.org/10.1007/BF01691158

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01691158

Keywords

Navigation